Dyslipidemia in HIV patients

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 12, 2005, Pages 1113-1120

  Tungsiripat, Marisa ^a   Aberg, Judith A ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450 3A4; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ISOENZYME; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG SUBSTITUTION; DYSLIPIDEMIA; ENZYME INHIBITION; ETHNOLOGY; GENDER; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; REVIEW;

ANTI-RETROVIRAL AGENTS; ANTILIPEMIC AGENTS; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS;

EID: 33644872002     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.12.1113     Document Type: Article

References (44)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. US Centers for Disease Control and Prevention. Deaths: prelimimary data for 2001. Available at:www.cdc.gov/nchs/data/nvsr/nvsr5l/nvsr5l_05.pdf. Last accessed accessed September 19, 2005.
3. US Centers for Disease Control and Prevention. Deaths: final data for 1987-1999 and preliminary data for 2000. Available at www.cdc.gov/nchs/ deaths.htm. Last accessed September 26, 2005.
4. US Centers for Disease Control and Prevention. Preventing Heart Disease and Stroke. Available at www.cdc.gov/nccdphp/bb_heartdisease/index.htm. Last accessed September 19, 2005.
5. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
6. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90:154-162.
7. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11:938-939.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
9. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27:77-81.
10. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.
11. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:e19.
12. Gallant JE, Staszewski S, Pozniak AL, at al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
13. Kumar P, Rodriguez-French A, Thompson M. Prospective Study of Hyperlipidemia in ART-naive Subjects taking Combivir/Abacavir (COM/ABC), COM/ Nelfinavir (NFV), or Stavudine (d4t)/Lam ivudine (3TC)/ NFV (ESS40002) [abstract no. 33]. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 24-28, 2002.
14. Cheng A. et al. 2-year long-term safety profile of tenofovir DF (TDF) in treatment-experienced patients from randomized, double-blind, placebo-controlled clinicals [abstract 7.3/7]. 9th European AIDS Conference (9th EACS), Warsaw, Poland, October 25-29, 2003.
15. Gilead Sciences, personal communication.
16. Murphy RL, Sanne I. Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17:2603-2614.
17. Kumar P, Willimas V, Tashima K, et al. Determinants of hyperlipidemia in ARV-naive subjects treated with trizivir (TZV), combivir (COM)/ nelfinavir (NFV), or stavudine (d4t)/lamivudine (3TC/NFV (abstract 713]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8-11, 2004.
18. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
19. Klein D, Hurley L, Quesenberry C. Hospitalizations for CHD and MI among Northern California HIV+ and HIV- Med: additional follow-up and changes in practice. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25, 2005.
20. Friis-Moller N, Sabin CA. Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
21. Dube MP Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
22. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
23. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
24. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288:2998-3007.
25. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
26. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
27. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227-239.
28. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97:946-952.
29. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577.
30. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS 2000; 14:13-18.
31. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004; 94:882-888.
32. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. The effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of ACTG 5108 study. J Acquir Immune Defic Syndr 2005; 39:307-312.
33. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hyper-triglyceridaemia. AIDS 2002; 16:2195-2200.
34. Gerber MT, Mondy KE, Yarasheski KE, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004; 39:419-425.
35. De Truchis P, Kirstetter M, Perier A. Treatment of hypertriglyceridemia in HIV-infected patients under HAART, by (n-3) polyunsaturated fatty acids: a double-blind randomized prospective trial in 122 patients [abstract 39]. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25, 2005.
36. Wohl D, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005; 41:1498-1504.
37. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: ACTG 5087. AIDS Res Hum Retroviruses 2005; 21:757-767.
38. Viracept [package insert]. La Jolla, CA: Aguron Pharmaceuticals Inc, 2003.
39. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45:3445-3450.
40. Kaletra [package insert]. North Chicago, IL: Abbott Laboratories, 2004.
41. Lexiva [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc.
42. Wire M, Baker K. Moore K. The pharmacokinetic (PK) interaction of GW433908 (908) with atorvastatin (ATO) and 908/ritonavir (RTV) with ATO (AVP 10013) [abstract no. A-1622]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 14-17, 2003.
43. Gerber JG, Rosenkranz SL, Fichtenbaum CJ. The effect of efavirenz and nelfinavir on the pharmacokinetics of pravastatin [abstract no. 870]. 2nd International Conference on HIV Pathogenesis and Treatment, July 13-16, 2003.
44. Carr R, Andre A, Bertz R. Concomitant administration of ABT-378/ ritonavir (ABT-378/r). Results in a clinically important pharmacokinetic (PK) interaction with atorvastatin but not pravastatin [abstract no. 1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000.